Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lin BioScienceROCO:6696 -6.18%26 PB Ratio is 5.39 as of Jul. 19, 2026, which is 68% below its 10-year median of 16.85. GuruFocus rates ROCO:6696 with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Lin BioScience ranks worse than 72.08% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-19), Lin BioScience's share price is NT$698.00. Lin BioScience's Book Value per Share for the quarter that ended in Dec. 2025 was NT$129.58. Hence, Lin BioScience's PB Ratio of today is 5.39.
Good Sign:
Lin BioScience Inc stock PB Ratio (=5.39) is close to 5-year low of 5.39.
The historical rank and industry rank for Lin BioScience's PB Ratio or its related term are showing as below:
ROCO:6696'
s PB Ratio Range Over the Past 10 Years
Min: 3.42 Med: 16.85 Max: 91.1
Current: 5.39
During the past 10 years, Lin BioScience's highest PB Ratio was 91.10. The lowest was 3.42. And the median was 16.85.
ROCO:6696's PB Ratio is ranked worse than 72.08% of 1232
companies
in the Biotechnology industry
Industry Median: 2.825
vs ROCO:6696: 5.39
During the past 12 months, Lin BioScience's average Book Value Per Share Growth Rate was 259.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 98.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 61.00% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Lin BioScience was 98.00% per year. The lowest was -33.30% per year. And the median was 27.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lin BioScience PB Ratio Related Terms
Lin BioScience PB Ratio Historical Data
* Premium members only.
The historical data trend for Lin BioScience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6696 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Lin BioScience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lin BioScience PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lin BioScience's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lin BioScience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Lin BioScience's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lin BioScience (ROCO:6696) has a PB Ratio of 5.39 as of Jul. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lin BioScience and its competitors. This is 68% below median its historical median of 16.85. Over the past decade, Lin BioScience's PB Ratio has ranged from 3.42 to 91.10. According to the industry distribution chart, Lin BioScience ranks #888 out of 1232 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Lin BioScience's PB Ratio too high?
Lin BioScience's current PB Ratio of 5.39 is 68% below median its 10-year median of 16.85. Over the past 10 years, this metric has ranged from a low of 3.42 to a high of 91.10. The Biotechnology industry median PB Ratio is 2.83. Lin BioScience's value of 5.39 is 90.8% above this industry median. Based on the distribution chart, Lin BioScience ranks #888 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lin BioScience has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lin BioScience's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lin BioScience ranks #888 out of 1232 companies for PB Ratio. This places Lin BioScience in the lower half of its industry. The industry median PB Ratio is 2.83. Lin BioScience's value of 5.39 is 90.8% above this benchmark. Historically, Lin BioScience's own PB Ratio has ranged from 3.42 to 91.10 over the past decade. While the company's 10-year median is 16.85 vs. the industry median of 2.83, Lin BioScience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lin BioScience's current PB Ratio of 5.39 is 90.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lin BioScience and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lin BioScience's current PB Ratio is 5.39, which is 68% below median its own 10-year median of 16.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lin BioScience stock overvalued right now?
Lin BioScience (ROCO:6696) has a current PB Ratio of 5.39. The current PB Ratio is 5.39, which is 68% below median its 10-year median of 16.85 and 90.8% above the Biotechnology industry median of 2.83. Lin BioScience's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lin BioScience (ROCO:6696), the current PB Ratio is 5.39 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.
26GF Score
Get the complete analysis for ROCO:6696
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6696 has been successfully added to your 
